CARBOPLATIN desensitisation

INDICATION (ICD10)

1. Carboplatin desensitisation for carboplatin hypersensitivity.
   PS 0, 1, 2

REGIMEN

Day 0	**Premedication** starting the night prior to infusion: Dexamethasone 8mg twice daily orally Cetirizine 10mg once daily orally H_2 antagonist once daily orally			
Day 1	**Premedication** 30 minutes prior to infusion: Dexamethasone 8mg IV bolus Chlorphenamine 10mg IV bolus Ondansetron 8mg IV bolus H_2 antagonist			
	CARBOPLATIN	AUC 0.005	IV infusion	50ml glucose 5% over 30 minutes
	CARBOPLATIN	AUC 0.05	IV infusion	50ml glucose 5% over 30 minutes
	CARBOPLATIN	AUC 0.5	IV infusion	50ml glucose 5% over 30 minutes
	CARBOPLATIN	AUC 4.445	IV infusion	#ml glucose 5% over 60 minutes

Dose calculated by EDTA GFR or calculated (CrCl + 25) x AUC.

diluent volume for dose prescribed as per national standardised product specification

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 21 days for the equivalent number of cycles would have received in treatment reacted to, up to 6 cycles

ANTI-EMETICS

Moderate risk day 1

CONCURRENT MEDICATION REQUIRED

Carboplatin	Ensure premedication given before carboplatin. Anaphylaxis treatment should be prescribed if the patient has had an anaphylactic episode previously. Dexamethasone 20mg IV bolus Chlorphenamine 10mg IV bolus H_2 antagonist Carboplatin should be given at a slower rate e.g 2-4 hours.

EXTRAVASATION AND TYPE OF LINE / FILTERS

Carboplatin - irritant

Filter not required
Peripheral or central line

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E including Mg^{++} (>0.4) and LFTs Neutrophils x 10^9/L ≥1.0 provided patient is well Platelets ≥100x10^9/L	baseline and every cycle
GFR assessed using EDTA result (BMI <19 or >30 or calculated creatinine clearance at the Consultant's discretion	baseline and every cycle
Patients with hydronephrosis or serum creatinine ≥100micromol/L	baseline and every cycle
CA125	baseline and day 1 every cycle
Virology	before cycle 1 if not previously checked
Weight	baseline and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Carboplatin	Ototoxicity – monitor Neurotoxicity - monitor

DOSE MODIFICATIONS

Hepatic impairment

Carboplatin

No need for dose adjustment is expected

Renal impairment

Carboplatin

GFR/ calculated CrCl ≤20ml/min or ≤30ml/min with pre-existing severe renal impairment	contraindicated

REFERENCES

1. Royal Marsden desensitisation regimen

Assessments

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Ongoing
Clinical assessment	X		Pre cycle		Pre cycle	Every cycle
SACT assessment (PS and toxicities)	X	X	X	X	X	Every cycle
FBC	X	X	X	X	X	Every cycle
U&E, calcium, magnesium & LFT	X	X	X	X	X	Every cycle
CrCl	X	X	X	X	X	Every cycle
CT scan	X					At cycle 6, Inform consultant team if not booked
Informed consent	X					Verbal each cycle
Height	X					
Weight recorded	X	X	X	X	X	Every cycle